Federal COVID-19 Response Leaves Some Cannabis Businesses in the Cold

Written by Darren Kaplan & Jana Weltzin As businesses around the United States reckon with the unfolding realities of the COVID-19 pandemic, the cannabis industry has continued to experience the consequences of divergent federal and state policies. On one hand, the hemp side of the cannabis industry is reaping the rewards of national legalization by

By |2020-04-10T09:08:54-06:00April 9th, 2020|Government and Policy|

The Hoban Minute – 25 Breaking News: DEA Removes Epidiolex From Controlled Substances List

The Hoban Minute - 25 Breaking News: DEA Removes Epidiolex From Controlled Substances List On April 6th, the DEA announced that Epidiolex, the first Cannabis-formulated drug to be approved by the FDA in 2018, was being removed from the Controlled Substances List. Bob and Eric discuss the significance of this development, and whether it will

By |2020-07-08T15:46:43-06:00April 8th, 2020|The Hoban Minute|

FDA Issues Warning Letter to CBD Company for Fraudulent COVID-19 Treatment Claims

On Tuesday, the Food and Drug Administration (“FDA”) and the Federal Trade Commission (“FTC”) issued a Warning Letter issued to Neuro XPF, a company selling CBD products in the U.S., based on claims contained on its website and social media pages that its products can mitigate, prevent, treat, diagnose, or cure COVID-19. The FDA has

By |2020-04-03T15:12:28-06:00April 2nd, 2020|Government and Policy|

Trade groups irked with FDA following CBD report to Congress

FDA’s 15-page report to the House and Senate appropriations committees was met with criticism from some leaders in the natural products and hemp industries, who have said the agency is dragging its heels on actively regulating a hemp-derived compound that has proliferated in U.S. products marketed as dietary supplements. FDA last week told Congress it’s

By |2020-07-08T15:48:52-06:00April 1st, 2020|HLG In The News|

Just in Time for the Holidays: FDA’s Updated Guidance on CBD Amid More Warning Letters

FDA Update Despite the impending Thanksgiving holiday, the U.S. Food and Drug Administration (“FDA”) kept plenty busy this week in keeping the hemp industry on its toes issuing: (a) yet another round of a whopping fifteen (15) warning letters to companies purportedly marketing “unapproved new drugs” containing hemp-derived cannabidiol (“CBD”) in violation of FDA regulations;

By |2019-12-18T13:08:47-07:00December 5th, 2019|Government and Policy|

Will Congress Provide Direction to FDA?

Earlier this week, as part of the Senate Appropriations Agriculture Subcommittee meeting, Senator Mitch McConnell (KY) submitted language concerning hemp-derived products and the FDA’s lingering uncertainty concerning the same as a potential proposal to be included as part of forthcoming budgetary legislation. The forthcoming proposed budget provides $2 million to the FDA for research, policy

By |2019-12-18T12:29:41-07:00September 20th, 2019|Government and Policy|